MX2022003628A - Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. - Google Patents

Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.

Info

Publication number
MX2022003628A
MX2022003628A MX2022003628A MX2022003628A MX2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A
Authority
MX
Mexico
Prior art keywords
treatment
cell carcinoma
squamous cell
patients
locally advanced
Prior art date
Application number
MX2022003628A
Other languages
English (en)
Inventor
Claudio Zanna
Silvano Brienza
Altman Sergio Adrian Szyldergemajn
Jean Bourhis
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2022003628A publication Critical patent/MX2022003628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos de administración de inhibidores de la proteína de apoptosis ("IAP"), o sales farmacéuticamente aceptables de la misma, para el tratamiento de un paciente humano que tiene carcinoma de células escamosas localmente avanzado.
MX2022003628A 2019-09-25 2020-09-25 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. MX2022003628A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962905703P 2019-09-25 2019-09-25
US202063016762P 2020-04-28 2020-04-28
EP20184601 2020-07-07
PCT/EP2020/076994 WO2021058794A1 (en) 2019-09-25 2020-09-25 Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Publications (1)

Publication Number Publication Date
MX2022003628A true MX2022003628A (es) 2022-07-21

Family

ID=72644266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003628A MX2022003628A (es) 2019-09-25 2020-09-25 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.

Country Status (11)

Country Link
EP (1) EP4034102A1 (es)
JP (1) JP2022550037A (es)
KR (1) KR20220088700A (es)
CN (1) CN114727984A (es)
AU (1) AU2020356356A1 (es)
BR (1) BR112022005624A2 (es)
CA (1) CA3151770A1 (es)
CO (1) CO2022004947A2 (es)
IL (1) IL291682A (es)
MX (1) MX2022003628A (es)
WO (1) WO2021058794A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101071516B1 (ko) 2006-05-05 2011-10-10 더 리젠츠 오브 더 유니버시티 오브 미시간 2가 ｓｍａｃ 모방체 및 그의 용도
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100113326A1 (en) 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
EP2139490B1 (en) 2007-04-13 2014-07-02 The Regents of the University of Michigan Diazo bicyclic smac mimetics and the uses thereof
ES2882855T3 (es) 2008-05-16 2021-12-02 Dana Farber Cancer Inst Inc Inmunomodulación por inhibidores de IAP
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8815927B2 (en) 2009-10-23 2014-08-26 The Regents Of The University Of Michigan Bivalent diazo bicyclic Smac mimetics and the uses thereof
CA2789879A1 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CN102666588A (zh) 2009-11-05 2012-09-12 Uab研究基金会 治疗基底细胞样基因型癌症
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
RU2649975C2 (ru) 2012-08-23 2018-04-06 Дзе Реджентс Оф Дзе Юнивёрсити Оф Мичиган Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения
EP2925764B1 (en) 2012-11-30 2023-03-01 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
CA2933939C (en) 2013-12-20 2021-03-16 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
ES2793286T3 (es) * 2014-12-09 2020-11-13 Chai Tai Tianqing Pharmaceutical Group Co Ltd Derivado de quinolina contra carcinoma de pulmón no microcítico
CA2916970A1 (en) 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
EP3419643A4 (en) 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. SMC COMBINATION THERAPY FOR TREATING CANCER
EP3600387A1 (en) 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Anticancer combination therapy

Also Published As

Publication number Publication date
EP4034102A1 (en) 2022-08-03
KR20220088700A (ko) 2022-06-28
CA3151770A1 (en) 2021-04-01
BR112022005624A2 (pt) 2022-07-12
AU2020356356A1 (en) 2022-05-12
WO2021058794A1 (en) 2021-04-01
CO2022004947A2 (es) 2022-08-30
IL291682A (en) 2022-05-01
CN114727984A (zh) 2022-07-08
JP2022550037A (ja) 2022-11-30

Similar Documents

Publication Publication Date Title
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2016008362A (es) Combinaciones farmaceuticas.
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MX2021002321A (es) Nuevos metodos.
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2022000143A (es) Metodos novedosos.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.
UA115250C2 (uk) Фармацевтичні комбінації
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
TW201642906A (en) Fixed dose combination for pain relief without edema
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.